- Treating intellectual property as an investment, and subjecting it to treaty arbitration, can have undesirable impact
- The expanding universe of IP
- CCI to investigate Swiss drugmaker Roche over breast cancer biosimilar
- Indian competition commission issues a path breaking order on abuse of dominant position in pharmaceuticals
- TPP May Be Dead but Big Pharma’s Still Getting Away with Murder
Category Archives: Special 301 report
In the early 1990s, Eli Lilly applied for patent protection in Canada for two chemical compounds, olanzapine and atomoxetine. The company had already obtained patents over the compounds, but asserted that it had evidence to support new uses for the … Continue reading
The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List – the latter includes countries that are alleged … Continue reading
By Kritika Suneja, ET Bureau| April 27, 2016 NEW DELHI: India continues to figure in the US’ Priority Watch List that identifies trade barriers to US companies due to intellectual property laws of other countries.
BY WILLIAM NEW, INTELLECTUAL PROPERTY WATCH| April 27, 2016 The Office of the United States Trade Representative (USTR) does not hesitate to add even its closest friends to its annual list of concerns about possible inadequate protection of US intellectual … Continue reading
Source: Hindu BusinessLine | APRIL 25, 2016 India has said that the US Special 301 report, which tries to put pressure on countries to enhance their intellectual property rights (IPRs) legislation, violated World Trade Organization (WTO) rules.
The annual IP report is expected soon By KM Gopakumar, The Hindu BusinessLine The Special 301 Report, an annual feature from the US that evaluates global intellectual property (IP) protection and enforcement in other countries, is expected to be out … Continue reading
By Zeba Siddiqui, Reuters|March 9, 2016 India has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western drugmakers, a U.S. business advocacy group said.